STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (31,837,205)	$ (14,363,287)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	650,131	632,915
Share based payments for services	530,736	232,847
Share-based payments for interest	80,716	0
Equity based compensation	2,743,267	1,380,500
Common stock contributed to 401(k) plan	145,090	151,308
Shares issued for settlement of clinical research costs	5,507,400	1,310,400
Write off of prepaid research and development	471,157	0
Loss on retired equipment	0	1,187
Loss (gain) on derivative instruments	8,643,561	(11,007,215)
Amortization of debt discount	1,956,424	917,692
Inducement expense	291,234	0
Capitalized lease interest	168,037	200,902
(Increase)/decrease in assets:
Receivables	99,824	(129,307)
Prepaid expenses	153,102	151,909
Inventory used for R&D and manufacturing	27,284	336,120
Deposits	150,000	154,995
Increase/(decrease) in liabilities:
Accounts payable	(2,514,488)	5,420,816
Accrued expenses	(731,388)	558,026
Due to employees	71,110	256,303
Other liabilities	4,450	1,995
Net cash used in operating activities	(13,389,558)	(13,791,894)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(1,015)	(10,525)
Expenditures for patent costs	(57,125)	(6,477)
Net cash used in investing activities	(58,140)	(17,002)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	11,596,652	10,519,306
Proceeds from employee stock purchases	385,000	0
Proceeds from issuance of notes payable	0	2,745,000
Proceeds from exercise of warrants	9,412,964	0
Payments on obligations under capital lease	(6,312)	(3,968)
Net cash provided by financing activities	21,388,304	13,260,338
NET DECREASE IN CASH AND CASH EQUIVALENTS	7,940,606	(548,558)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	2,369,438	2,917,996
CASH AND CASH EQUIVALENTS, END OF YEAR	10,310,044	2,369,438
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Prepaid amount under consulting services paid with issuance of common stock	162,452	(3,339)
Conversion of accrued salaries and fees to notes payable	0	275,000
Conversion of notes payable to common stock	2,294,300	450,700
Exercise of derivative liabilities	1,379,899	0
Fair value of warrants issued in connection with public offering	0	(4,665,683)
Lease payments included in accounts payable at year end	415	1,890
Financing costs included in accounts payable at year end	46,599	35,605
Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services	0	(305,341)
Cash paid for interest expense	$ 1,750,897	$ 1,888,612